
Aura Biosciences, Inc.: updates and filings
Price
$6.87
November 20, 2026Market cap $715M
What Ploutos Investor adds for Aura Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
- 11MonReportQuarterly report · for the period to Mar 31, 2026Document
- 11MonResultsResults of operations, other material eventsDocument
- 5TueDealMaterial agreement enteredDocument
- 4MonDealMaterial agreement entered, results of operations, other material eventsDocument
- 4MonPeopleOfficer or director change, Regulation FD disclosure, other material eventsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, other material eventsForm8-K
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 1, 2026Shares registered for employeesFormS-8
- Aug 20, 2026FilingFormEFFECT
- Aug 18, 2026Correspondence with the SECFormCORRESP
- Aug 17, 2026Letter from the SECFormUPLOAD
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Shelf registration for future offeringsFormS-3
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operations, restructuring costs, officer or director change, other material eventsForm8-K
- Aug 5, 2026Shareholder voteForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 8, 2026Officer or director changeForm8-K
- Jun 29, 2026Annual meeting proxy statementFormDEF 14A
- Jun 17, 2026Preliminary proxy statementFormPRE 14A
- Jun 11, 2026Shareholder voteForm8-K
- May 19, 2026Shares registered for employeesFormS-8
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, other material events | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 1, 2026 | S-8 | Shares registered for employees | Document |
| Aug 20, 2026 | EFFECT | Filing | Document |
| Aug 18, 2026 | CORRESP | Correspondence with the SEC | Document |
| Aug 17, 2026 | UPLOAD | Letter from the SEC | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations, restructuring costs, officer or director change, other material events | Document |
| Aug 5, 2026 | 8-K | Shareholder vote | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 8, 2026 | 8-K | Officer or director change | Document |
| Jun 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jun 17, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Jun 11, 2026 | 8-K | Shareholder vote | Document |
| May 19, 2026 | S-8 | Shares registered for employees | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 21, 2010.
The full analysis
What do Aura Biosciences's filings show?
The filings are where every one of Aura Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.